Lead Product(s) : PRX012
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prothena to Present Data from Two of its Alzheimer’s Disease Programs
Details : PRX012 is a next-generation, high-potency monoclonal antibody designed to deliver best-in-class efficacy, safety and patient experience for the treatment of AD. PRX012 binds to the N-terminus of Aβ, a key component of the plaques associated with AD.
Product Name : PRX012
Product Type : Antibody
Upfront Cash : Inapplicable
July 20, 2021
Lead Product(s) : PRX012
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable